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activity, which was determined with exogenic ATP, is higher than in
control animals, whereas the enzyme's activity, which used endogenic
ATP is lower than in CM of control animals. In both cases, the HK activity
was normalized to the control levels after feeding of rats with nobiletin.
These data suggest that nobiletin could enhance mitochondrial ATP
synthesis in hypothyroidism through activation of matrix substrate-
level phosphorylation, which may be relevant for the prevention and
treatment of hypometabolic disorders.
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Ullrich Congenital Muscular Dystrophy (UCMD) and Bethlem
Myopathy (BM) are inherited muscle diseases due to mutations in
the genes encoding the extracellular matrix protein collagen (Col)
VI. Opening of the cyclosporin A-sensitive mitochondrial permeabil-
ity transition pore is a causative event in disease pathogenesis, and a
potential target for therapy. Here we have tested the effect of N-
methyl-4-isoleucine-cyclosporin (NIM811), a non-immunosuppressive
cyclophilin inhibitor, in a zebraﬁsh model of ColVI myopathy
obtained by deletion of the N-terminal region of the ColVI α1 triple
helical domain, a common mutation of UCMD. Treatment with
antisense morpholino sequences targeting col6a1 exon 9 at the 1–4
cell stage (within 1 hour post fertilization, hpf) caused severe
ultrastructural and motor abnormalities as assessed by electron
and ﬂuorescence microscopy, birefringence, spontaneous coiling
events and touch-evoked responses measured at 24–48 hpf. Struc-
tural and functional abnormalities were largely prevented when
NIM811 – which proved signiﬁcantly more effective and less toxic
than cyclosporin A –was administered at 21 hpf. Beneﬁcial effects of
NIM811 were also detected (i) in primary muscle-derived cell
cultures from UCMD and BM patients, where the typical mitochon-
drial alterations and depolarizing response to rotenone and
oligomycin were signiﬁcantly reduced; and (ii) in the Col6a1−/−
myopathic mouse model, where apoptosis was prevented and
muscle strength was increased. Since the permeability transition
pore of zebraﬁsh shares its key regulatory features with the
mammalian pore our results suggest that early treatment with
NIM811 should be tested as a potential therapy for UCMD and BM.
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